Acute Treatments for Episodic Migraine

医学 特里普坦 里扎曲普坦 偏头痛 苏马曲普坦 安慰剂 麻醉 随机对照试验 佐米曲普坦 不利影响 双氯芬酸 观察研究 系统回顾 二氢麦角胺 内科学 梅德林 替代医学 法学 受体 兴奋剂 病理 政治学
作者
Rashmi B. Halker Singh,Juliana H. VanderPluym,Allison S. Morrow,Meritxell Urtecho,Tarek Nayfeh,Victor D. Torres Roldan,Magdoleen H. Farah,Bashar Hasan,Samer Mohir Saadi,Sahrish H Shah,Rami Abd‐Rabu,Lubna Daraz,Larry J. Prokop,Mohammad Hassan Murad,Zhen Wang
标识
DOI:10.23970/ahrqepccer239
摘要

Objectives. To evaluate the effectiveness and comparative effectiveness of pharmacologic and nonpharmacologic therapies for the acute treatment of episodic migraine in adults. Data sources. MEDLINE®, Embase®, Cochrane Central Registrar of Controlled Trials, Cochrane Database of Systematic Reviews, PsycINFO®, Scopus, and various grey literature sources from database inception to July 24, 2020. Comparative effectiveness evidence about triptans and nonsteroidal anti-inflammatory drugs (NSAIDs) was extracted from existing systematic reviews. Review methods. We included randomized controlled trials (RCTs) and comparative observational studies that enrolled adults who received an intervention to acutely treat episodic migraine. Pairs of independent reviewers selected and appraised studies. Results. Data on triptans were derived from 186 RCTs summarized in nine systematic reviews (101,276 patients; most studied was sumatriptan, followed by zolmitriptan, eletriptan, naratriptan, almotriptan, rizatriptan, and frovatriptan). Compared with placebo, triptans resolved pain at 2 hours and 1 day, and increased the risk of mild and transient adverse events (high strength of the body of evidence [SOE]). Data on NSAIDs were derived from five systematic reviews (13,214 patients; most studied was ibuprofen, followed by diclofenac and ketorolac). Compared with placebo, NSAIDs probably resolved pain at 2 hours and 1 day, and increased the risk of mild and transient adverse events (moderate SOE). For other interventions, we included 135 RCTs and 6 comparative observational studies (37,653 patients). Compared with placebo, antiemetics (low SOE), dihydroergotamine (moderate to high SOE), ergotamine plus caffeine (moderate SOE), and acetaminophen (moderate SOE) reduced acute pain. Opioids were evaluated in 15 studies (2,208 patients).Butorphanol, meperidine, morphine, hydromorphone, and tramadol in combination with acetaminophen may reduce pain at 2 hours and 1 day, compared with placebo (low SOE). Some opioids may be less effective than some antiemetics or dexamethasone (low SOE). No studies evaluated instruments for predicting risk of opioid misuse, opioid use disorder, or overdose, or evaluated risk mitigation strategies to be used when prescribing opioids for the acute treatment of episodic migraine. Calcitonin gene-related peptide (CGRP) receptor antagonists improved headache relief at 2 hours and increased the likelihood of being headache-free at 2 hours, at 1 day, and at 1 week (low to high SOE). Lasmiditan (the first approved 5-HT1F receptor agonist) restored function at 2 hours and resolved pain at 2 hours, 1 day, and 1 week (moderate to high SOE). Sparse and low SOE suggested possible effectiveness of dexamethasone, dipyrone, magnesium sulfate, and octreotide. Compared with placebo, several nonpharmacologic treatments may improve various measures of pain, including remote electrical neuromodulation (moderate SOE), magnetic stimulation (low SOE), acupuncture (low SOE), chamomile oil (low SOE), external trigeminal nerve stimulation (low SOE), and eye movement desensitization re-processing (low SOE). However, these interventions, including the noninvasive neuromodulation devices, have been evaluated only by single or very few trials. Conclusions. A number of acute treatments for episodic migraine exist with varying degrees of evidence for effectiveness and harms. Use of triptans, NSAIDs, antiemetics, dihydroergotamine, CGRP antagonists, and lasmiditan is associated with improved pain and function. The evidence base for many other interventions for acute treatment, including opioids, remains limited.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
黄油可颂完成签到,获得积分10
1秒前
1秒前
2秒前
坦率向薇完成签到,获得积分20
2秒前
财务自由发布了新的文献求助10
2秒前
3秒前
nanjincn发布了新的文献求助150
3秒前
xixilamn完成签到,获得积分10
3秒前
勿念那份执着完成签到,获得积分10
4秒前
吴呜呜发布了新的文献求助10
4秒前
4秒前
lee123发布了新的文献求助10
4秒前
Ezio_sunhao完成签到,获得积分10
5秒前
谨慎的破茧完成签到,获得积分10
5秒前
zzz发布了新的文献求助10
6秒前
6秒前
I7发布了新的文献求助10
6秒前
幽默的亦寒完成签到,获得积分10
7秒前
7秒前
qcyyyyy完成签到,获得积分10
7秒前
8秒前
8秒前
zyq完成签到,获得积分10
8秒前
庾傀斗发布了新的文献求助10
8秒前
研友_VZG7GZ的应助被张远幸采纳,获得10
10秒前
10秒前
嘟嘟完成签到,获得积分10
12秒前
领导范儿的应助被777采纳,获得10
12秒前
吴境完成签到,获得积分20
12秒前
科研通AI6.3的应助被静候灵归采纳,获得10
14秒前
14秒前
mm发布了新的文献求助10
14秒前
科研通AI2S的应助被zyy采纳,获得10
14秒前
如意的雅蕊完成签到,获得积分10
14秒前
科研通AI2S的应助被嘟嘟采纳,获得10
15秒前
科研通AI6.4的应助被obcx采纳,获得10
15秒前
草草完成签到 ,获得积分10
15秒前
在水一方的应助被初景采纳,获得10
16秒前
nn完成签到 ,获得积分10
16秒前
顾矜的应助被rainbow采纳,获得30
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187362
求助须知:如何正确求助?哪些是违规求助? 9575478
关于积分的说明 21841431
捐赠科研通 7785067
什么是DOI,文献DOI怎么找? 3434943
关于科研通互助平台的介绍 2559401
邀请新用户注册赠送积分活动 2481820